Clinical Trials Logo

Clinical Trial Summary

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.


Clinical Trial Description

This is a Phase III, randomized, multicenter, double-blind, placebo-controlled, study to evaluate the efficacy and safety of durvalumab adjuvant therapy compared to placebo in patients with completely resected stage II-III NSCLC who have undergone curative intent therapy (complete resection ± neoadjuvant and/or adjuvant therapy), who have no evidence of Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1-defined disease recurrence, and who become MRD+ during surveillance period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04642469
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date November 30, 2020
Completion date January 15, 2024